Research
Hormonal
Semaglutide improves cardiovascular outcomes, including reducing the risk of major adverse cardiovascular events (MACE), in patients with type 2 diabetes.
If you have type 2 diabetes and heart disease, kidney disease, or heart failure, ask your doctor about adding a GLP-1 RA like semaglutide. It can significantly lower your risk of heart attack, stroke, and heart failure, even if your blood sugar is already well-controlled.
StrongSupportsVERY_HIGH confidence
GLP-1 RA reduced MACE by 14% (P<0.0001)... GLP-1 RA reduced all-cause mortality by 12% (P=0.0001), hospital admission for heart failure by 11% (P=0.013), and the composite kidney outcome by 21% (P<0.0001)...
Why this rating
Based on systematic reviews and meta-analyses of randomized trials.
Source
An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review
Namrata Dagli et al. · Cureus · 2023
narrative_reviewCited 8×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →